

26 Jun 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: Lilly's latest acquisition; the outlook for Stelara biosimilars; better biomarkers needed in the TIGIT/PD-1 combo field?; Sanofi on the deal-making landscape; and the shifting KRAS race in China.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 June 2023, including: [Eli Lilly and Company's](#) latest acquisition; the outlook for Stelara biosimilars; better biomarkers needed in the TIGIT/PD-1 combo field?; Sanofi on the deal-making landscape; and the shifting KRAS race in China.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Lilly Wants To Gamble On Dice's Oral IL-17 Drugs For Psoriasis](#)" - Scrip, 20 Jun, 2023.)

(Also see "[History Repeats: Will US Stelara Settlements Follow Humira's Lead?](#)" - Scrip, 19 Jun, 2023.)

(Also see "[As Gilead's PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed](#)" - Scrip, 21 Jun, 2023.)

(Also see "[The Dealmaking Landscape According to Sanofi](#)" - Scrip, 15 Jun, 2023.)

SCRIP

CITELINE COMMERCIAL

(Also see "[China's KRAS Race: Homegrown Contenders Play Catch-Up](#)" - Scrip, 16 Jun, 2023.)

[Click here to explore this interactive content online](#) ✨